Wall Street analysts expect Unum Therapeutics Inc (NASDAQ:UMRX) to report earnings of ($0.35) per share for the current fiscal quarter, Zacks Investment Research reports. Two analysts have issued estimates for Unum Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.33) and the lowest estimate coming in at ($0.37). The business is scheduled to issue its next quarterly earnings results on Monday, February 11th.
According to Zacks, analysts expect that Unum Therapeutics will report full-year earnings of ($1.56) per share for the current financial year, with EPS estimates ranging from ($1.67) to ($1.44). For the next year, analysts anticipate that the company will post earnings of ($1.50) per share, with EPS estimates ranging from ($1.59) to ($1.42). Zacks Investment Research’s EPS averages are a mean average based on a survey of analysts that that provide coverage for Unum Therapeutics.
Unum Therapeutics (NASDAQ:UMRX) last announced its earnings results on Monday, November 12th. The company reported ($0.34) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.35) by $0.01. Unum Therapeutics had a negative net margin of 404.34% and a negative return on equity of 382.71%. The company had revenue of $2.04 million for the quarter, compared to analysts’ expectations of $2.29 million.
In related news, insider Seth Ettenberg sold 11,485 shares of Unum Therapeutics stock in a transaction that occurred on Thursday, October 25th. The shares were sold at an average price of $8.46, for a total value of $97,163.10. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders sold 34,455 shares of company stock worth $320,776 over the last three months.
A number of large investors have recently made changes to their positions in UMRX. Millennium Management LLC bought a new position in Unum Therapeutics in the first quarter valued at approximately $982,000. Jennison Associates LLC boosted its position in Unum Therapeutics by 4.3% in the second quarter. Jennison Associates LLC now owns 935,307 shares of the company’s stock valued at $13,305,000 after buying an additional 38,552 shares in the last quarter. Wasatch Advisors Inc. boosted its position in Unum Therapeutics by 5.3% in the second quarter. Wasatch Advisors Inc. now owns 267,625 shares of the company’s stock valued at $3,840,000 after buying an additional 13,525 shares in the last quarter. Bank of New York Mellon Corp acquired a new stake in Unum Therapeutics in the second quarter valued at approximately $177,000. Finally, Spark Investment Management LLC acquired a new stake in Unum Therapeutics in the second quarter valued at approximately $186,000. 51.81% of the stock is currently owned by institutional investors and hedge funds.
Shares of UMRX opened at $6.90 on Thursday. Unum Therapeutics has a 12 month low of $6.26 and a 12 month high of $17.66.
About Unum Therapeutics
Unum Therapeutics Inc, a clinical stage biopharmaceutical company, develops and commercializes immunotherapy products designed to harness the power of a patient's immune system to cure cancer. Its lead product candidate is the ACTR087 used in combination with rituximab, which is in Phase I clinical trials to treat adult patients with relapsed or refractory non-Hodgkin lymphoma.
Recommended Story: What is a Leveraged Buyout (LBO)?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Unum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.